Oncimmune Holdings PLC – ONC – Interim Results
Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, today announces its interim results for the six months ended 30 November 2020.
Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, today announces its interim results for the six months ended 30 November 2020.
31 October 2019 – Oncimmune Holdings plc (AIM:ONC.L), the leading global immunodiagnostics group, today announces its preliminary unaudited full year results for the year ended 31 May 2019. The audited full year results are expected to be available shortly.
Oncimmune Holdings plc (AIM:ONC.L), a leading global immunodiagnostics group, today provides the following business update for the year ended 31 May 2019.
Positive Top Line Results for Early Cancer Detection Test – Lung Cancer Scotland Study.
Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, today announces that it has signed an exclusive agreement for the distribution of its EarlyCDT-Lung test kit in Portugal with Sabartech S.L., its existing distributor in Spain.The agreement includes a minimum sales commitment of £700,000 over 5 years.
Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, today announces that its Spanish distributor, Sabartech, has signed an agreement to sell EarlyCDT-Lung as a screening test for the early detection of lung cancer through the hospitals and clinics of the Quirónsalud group.
Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, today announces its half year results for the six months ended 30 November 2018.
Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® liquid biopsy platform technology, today provides an update on the business ahead of its full year results for the year ended 31 May 2018, expected in October 2018.